Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 9/20 | 0.52 |
| ▸ | MIF | P14174 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CD74 | P04233 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CBX7 | O95931 | 2/20 | 0.39 |
| ▸ | CDYL | Q9Y232 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.39 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13341148 | 0.84 | MIF (0.50) | IDO1MIFKMT2ACD74MEN1 | |
| SCHEMBL16948291 | 0.82 | KMT2A (0.64) | MIFKMT2ACD74MEN1POLB | |
| SCHEMBL20172636 | 0.82 | MIF (0.46) | IDO1MIFKMT2ACD74MEN1 | |
| SCHEMBL16932362 | 0.79 | IDO1 (0.68) | IDO1 | |
| SCHEMBL30537991 | 0.79 | IDO1 (0.68) | IDO1 | |
| SCHEMBL25095615 | 0.79 | PPARG (0.46) | IDO1MIFKMT2AMEN1 | |
| SCHEMBL16939103 | 0.79 | KMO (0.48) | IDO1MIFKMT2ACD74MEN1 | |
| SCHEMBL21991037 | 0.78 | ALDH1A1 (0.51) | MIFKMT2AMEN1POLBL3MBTL1 | |
| SCHEMBL25462884 | 0.78 | IDO1 (0.45) | IDO1MIFKMT2ACD74MEN1 | |
| SCHEMBL25613249 | 0.78 | SIGMAR1 (0.49) | IDO1MIFKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667615-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-06-06 | — | — | US | disclosed |
| EP-3323814-B1 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | ASTRAZENECA AB (SE) | 2020-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667615-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | IDO1 362/4885MIF 4062/4885KMT2A 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.